期刊文献+

非手术疗法治愈慢性难愈合创面的临床实践 被引量:3

Clinical Application of Nonsurgical Treatment for Refractory Wounded Sites
下载PDF
导出
摘要 目的:探讨慢性难愈合创面修复的非手术治疗。方法选取40例患者慢性难愈合创面共46处,控制基础疾病,局部清创,纳米银抗菌医用敷料保护创面及外用抗生素药物,防止感染或感染继续扩散,并合理使用碱性成纤维细胞生长因子或重组人表皮生长因子,期间辅以氦氖激光照射治疗。结果46处创面均痊愈,时间为1~3个月,治疗过程中未发生感染加重甚至侵袭性感染等情况。结论对于慢性难愈合创面,通过积极创面处理,辅以正确的创面用药及适当理疗,同样可以达到较理想的创面愈合。 Objective To study the non-surgical methods as the restorative treatment with refractory wounds. Methods Totally forty six refractory wounded sites have been selected from forty patients. We cleaned the wound-ed sites and applied both nano silver medical paste and antibiotics to prevent them from infectious spreading. Ad-ditionally, either alkaline ifbroblast growth factor or recombinant epidermal growth factor has also been applied on these sites, followed by further exposing them under the lights of He and Ne. Results All wounded sites have been healed within one to three months. There is no aggravating or invasive infections observed during the treatment. Conclusion Refractory wounds could be well healed by active handling directed on these sites with the help of proper dosing and physical treatment. This complex treatment procedure could achieve a prefect healing result.
出处 《中国血液流变学杂志》 CAS 2013年第4期695-696,703,共3页 Chinese Journal of Hemorheology
关键词 慢性难愈合创面 修复 非手术疗法 refractory wounded site wound healing non-surgical treatment
  • 相关文献

参考文献6

二级参考文献25

  • 1付小兵,沈祖尧,陈玉林,谢君鹤,郭振荣,张明良,盛志勇.Recombinant bovine basic fibroblast growth factor accelerates wound healing in patients with burns, donor sites and chronic dermal ulcers[J].Chinese Medical Journal,2000(4):79-83. 被引量:26
  • 2付小兵,程飚,盛志勇.生长因子应用于临床创伤修复——十年的主要进展与展望[J].中国修复重建外科杂志,2004,18(6):508-512. 被引量:73
  • 3李晓芳,赵柏程,钱利,吴祖林.重组人表皮生长因子治疗烧伤创面的临床观察[J].中国现代医学杂志,2005,15(17):2683-2685. 被引量:11
  • 4Mohan VK.Recombinant human epidermal growth factor (RE-GEN-D 150):effect on healing of diabetic foot ulcers.Diabetes Res Clin Pract,2007,78(3):405-411.
  • 5Fernández-Montequín JI,Betancourt BY,Leyva-Gonzalez G,et al.Intralesional administration of epidermal growth factor-based formulation (Heberprot-P) in chronic diabetic foot ulcer:treatment up to complete wound closure.Int Wound J,2009,6(1):67-72.
  • 6Femández-Montequín JI,lnfante-Cristiá E,Valenzuela-Silva C,et al.Intralesional injections of Citoprot-P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation.Int Wound J,2007,4(4):333-343.
  • 7Cohen MA,Eaglstein WH.Recombinant human platelet-derived growth factor gel speeds healing of acute full-thickness punch biopsy wounds.J Am Acad Dermatol,2001,45(6):857-862.
  • 8Embil JM,Papp K,Sibbald G,et al.Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers; an open-label clinical evaluation of efficacy.Wound Repair Regen,2000,8(3):162-168.
  • 9Smiell JM,Wieman TJ,Steed DL,et al.Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing,lower extremity diabetic ulcers; a combined analysis of four randomized studies.Wound Repair Regen,1999,7(5):335-346.
  • 10Rees RS,Robson MC,Smiell JM,et al.Beraplermin gel in the treatment of pressure ulcers; a phase II randomized,doubleblind,placebo-controlled study.Wound Repair Regen,1999,7 (3):141-147.

共引文献211

同被引文献15

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部